ascopubs.org

Clinical Utility of CDK4/6 Inhibitors in Sarcoma: Successes and Future Challenges

Biomarkers for Cyclin-Dependent Kinase 4/6 Inhibitors in the Treatment of Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced/Metastatic Breast Cancer: Translation to ...
Medical Xpress

Breast cancer study reveals synergistic effect of CDK2 and CDK4/6 combination therapy

A new preclinical study from researchers at The University of Texas MD Anderson Cancer Center, published in Nature Communications, identifies a powerful strategy to overcome drug resistance in breast ...
Medscape

Delaying CDK4/6 Inhibitor Treatment to Second Line Saves Costs, Maintains Outcomes in Advanced Breast Cancer

In a phase 3 trial-based cost-effectiveness analysis for advanced breast cancer, treatment with cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors in the second line rather than the first line ...
Medical Xpress

Overexpressed Cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in some breast cancer

This study was carried out by Prof. Qiang Liu (Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University). In the study, researchers found that the palbociclib-resistant breast cancer ...
Medscape

Imlunestrant Benefit in Breast Cancer Holds After Progression on CDK4/6 Therapy

Combination therapy with imlunestrant and the CDK4/6 inhibitor abemaciclib led to a significant progression-free survival (PFS) benefit compared with imlunestrant alone in women with estrogen receptor ...
EurekAlert!

Overexpressed Cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in breast cancer that can be reversed by PI3K/mTOR Inhibitors

This study is carried out by Prof. Qiang Liu (Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University). In this study, researchers found that the palbociclib-resistant breast cancer ...
Hosted on MSN

Powerful New Evidence Finds CDK4/6 Inhibitors Reduce Recurrence Risk In The Largest Sub-Group of Breast Cancer Patients

For many many women diagnosed with early-stage, hormone receptor–positive (HR-positive), HER2-negative breast cancer, treatment after surgery usually includes hormone-blocking pills (called endocrine ...
MedPage Today

No Survival Benefit in Advanced Breast Cancer With Frontline CDK4/6 Inhibition

Frontline CDK4/6 inhibition showed no overall survival advantage compared to initiating treatment in the second-line. A post hoc analysis suggested improved survival with first-line CDK4/6 inhibition ...
idw

Systemische Therapie bei Brustkrebs – Leitlinienempfehlungen aktualisiert

Katrin Mugele Presse- und Öffentlichkeitsarbeit Deutsche Krebsgesellschaft e. V. Das Leitlinienprogramm Onkologie hat unter Federführung der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe e.V ...
Ärzteblatt

Fortgeschrittenes HR+/HER2- Mammakarzinom mit ESR1-Mutation: Selektiver Östrogenrezeptor-Degrader verzögert Progression um 6 Monate

Die endokrine Therapie mit einem Aromatasehemmer kann beim fortgeschrittenen HR+/HER2- Mammakarzinom versagen, wenn eine ESR1-Mutation vorliegen. Ein Wechsel vom Aromatasehemmer auf den ...